Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | PAR 21 055

Opportunity Information: Apply for PAR 21 055

The National Institutes of Health (NIH) funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number PAR-21-055) supports investigator-initiated research that adds a focused mechanistic study onto an already existing, ongoing clinical project. The main idea is to leverage active clinical studies, cohorts, or trials that are already enrolling participants or collecting samples and data, and then use that existing infrastructure to answer deeper "how and why" questions about underlying biological, behavioral, or other mechanisms relevant to human health. Because the funding mechanism is an R01 research project grant, the application is expected to propose a well-developed, hypothesis-driven ancillary study with clear aims, strong scientific rationale, and a feasible plan that fits alongside the parent clinical project without disrupting it.

A key feature of this opportunity is the "Clinical Trial Not Allowed" designation. That means applicants cannot propose a new clinical trial as the ancillary study itself. In practical terms, the proposed work should not involve prospectively assigning human participants to an intervention or condition to evaluate the effect on health-related outcomes. Instead, the grant is meant to fund mechanistic investigations that take advantage of participants, measurements, clinical data, or biospecimens being collected as part of an existing clinical project. Typical examples of what this kind of mechanism often supports include laboratory analyses of stored or newly collected biospecimens, additional biomarker assays, immunologic or genomic profiling, advanced imaging analyses, physiologic or pharmacodynamic assessments, or other mechanistic measurements that can be layered onto the parent study. The ancillary study should be clearly connected to the parent project, scientifically additive (not duplicative), and realistically implementable within the timelines and operational constraints of the ongoing clinical work.

This opportunity sits in the NIH health research portfolio and is listed under CFDA number 93.846. It is categorized as a discretionary grant program and uses the grant funding instrument. While the excerpted source data does not list an expected number of awards, it does provide an award ceiling of $300,000, which signals a budget expectation or maximum for the opportunity as presented in the dataset (applicants would still need to follow the specific budget rules and guidance in the full announcement and NIH policies). The original closing date shown in the source data is 2022-11-21, and the opportunity record creation date is 2020-10-22. Since NIH opportunities can be reissued, updated, or replaced over time, anyone considering submission would typically verify the current status and active receipt dates in the live NIH posting and related notices.

Eligibility is broad and includes many common U.S. applicant organization types. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofit organizations both with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal government agencies, regional organizations, and U.S. territories or possessions. These categories underline NIH's openness to a wide range of institutions capable of carrying out rigorous mechanistic research in connection with ongoing clinical studies.

At the same time, the opportunity includes important restrictions related to non-U.S. entities and components. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic (non-U.S.) foreign institutions are stated as not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement. In NIH terms, that generally means a U.S. applicant organization can include a foreign component in the project when it is scientifically justified and appropriately managed and disclosed, even though a foreign institution cannot serve as the primary applicant. This distinction matters for projects that may require specialized assays, unique populations, or collaborative resources outside the United States, while keeping the primary award and accountability with an eligible U.S.-based applicant.

Overall, PAR-21-055 is designed for researchers who already have access to an active clinical project and want to use that opportunity to do deeper mechanistic science that would be difficult or inefficient to run as a standalone study. The successful application would typically make a clear case that the ancillary mechanistic work is tightly integrated with the ongoing clinical project, provides high value for understanding disease processes or treatment responses, stays within the "no clinical trial" boundary, and can be completed using a realistic plan for coordination, data and specimen access, human subjects protections, and analytical rigor.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2020-10-22.
• Applicants must submit their applications by 2022-11-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 055

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: